Blenrep extended the time to disease progression ... in the first nine months of 2023. Prior to its launch, GSK had suggested it could eventually become a £3 billion blockbuster, assuming it ...

we have a significant opportunity to strengthen our oncology business with the launch of Blenrep in half-two, 2025. We filed for approval in the U.S., EMA, and Japan in the quarter. Next slide ...

Blenrep (belantamab mafodotin ... option for relapsed and refractory multiple myeloma. It’s a key new launch for GSK as it tries to rebuild its oncology business under chief scientific officer ...

Sales of the jab for respiratory syncytial virus (RSV), previously a key driver of vaccine sales which saw an extremely ...

Sales of the jab for respiratory syncytial virus (RSV), previously a key driver of vaccine sales which saw an extremely successful launch last ... next year.” Blenrep, a treatment for cancer ...

Sales of the jab for respiratory syncytial virus (RSV), previously a key driver of vaccine sales which saw an extremely successful launch last year ... built into GSK’s portfolio and performance”.